COV Currently holding shares: Gapping down on acquisition. Considering adding to position. Covidien enters definitive agreement to acquire Somanetics for $25/shr in cash, a deal valued at $250M (approximately 32% premium to prior close) There is a case for a 5-7 day consolidation/pullback period